Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Short Interest Update

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) saw a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 56,514 shares, a growth of 172.7% from the August 15th total of 20,724 shares. Based on an average daily trading volume, of 950,731 shares, the short-interest ratio is presently 0.1 days. Currently, 1.2% of the company’s shares are short sold.

Institutional Investors Weigh In On Evaxion A/S

A number of institutional investors and hedge funds have recently modified their holdings of the business. Rathbones Group PLC purchased a new stake in Evaxion A/S in the first quarter worth $170,000. Renaissance Technologies LLC purchased a new stake in shares of Evaxion A/S during the first quarter valued at $146,000. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in shares of Evaxion A/S during the first quarter valued at $112,000. SmartHarvest Portfolios LLC bought a new position in shares of Evaxion A/S in the fourth quarter worth about $72,000. Finally, Northwestern Mutual Wealth Management Co. bought a new position in shares of Evaxion A/S in the fourth quarter worth about $38,000. 11.04% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 9th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Evaxion A/S Stock Performance

Evaxion A/S stock opened at $3.13 on Friday. Evaxion A/S has a 1-year low of $2.77 and a 1-year high of $12.15. The company’s 50-day moving average is $3.09 and its 200 day moving average is $3.54. The firm has a market capitalization of $26.10 million, a P/E ratio of -2.59 and a beta of 0.26. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.06 and a quick ratio of 5.06.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.